India, July 22 -- Cardiol Therapeutics Inc. (CRDL) is approaching a key clinical milestone related to its lead asset, CardiolRx.
CardiolRx (cannabidiol) oral solution is in clinical development for use in the treatment of heart disease.
A phase II study of CardiolRx in patients with acute myocarditis, dubbed ARCHER, is underway.
Acute myocarditis refers to an inflammatory condition of the heart muscle (myocardium), often resulting from viral infection. Its symptoms include chest pain, fatigue, shortness of breath, palpitations, edema, or swelling in the legs, ankles, and feet, and flu-like symptoms. There are no FDA-approved treatments for myocarditis, which is a major cause of sudden cardiac death in people under 35 and can lead to seve...